comparemela.com
Home
Live Updates
Henar Hevia - Breaking News
Pages:
Latest Breaking News On - Henar hevia - Page 2 : comparemela.com
Johnson & Johnson : receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
Media contact: Investor contact: .
France
Beerse
Region-flamande
Belgium
Saclay
France-general
Institut-curie
Henar-hevia
Nicolas-girard
Zayn-qureshi
European-medicines-agency
Johnson
Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC
Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.
Saint-quentin
Champagne-ardenne
France
Paris
France-general
Henar-hevia
Kiran-patel
Nicolas-girard
Institut-curie
Curie-montsouris-thorax-institute
Clinical-development
Johnson-research-development
vimarsana © 2020. All Rights Reserved.